Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study

被引：0
|
作者：
Tan, X. [1 ]
Wu, Z. [1 ]
Wang, Y. [1 ]
Yao, K. [1 ]
机构：
[1] Sun Yat Sen Univ, Urol, Canc Ctr, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.354
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218P
引用
收藏
页码：S1560 / S1560
页数：1
相关论文
共 50 条
  • [21] Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma: The potential impact of informative censoring
    Martini, Alberto
    Yu, Menggang
    Raggi, Daniele
    Joshi, Himanshu
    Fallara, Giuseppe
    Montorsi, Francesco
    Necchi, Andrea
    Galsky, Matthew D.
    CANCER, 2022, 128 (15) : 2892 - 2897
  • [22] Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274
    Galsky, Matthew D.
    Witjes, Johannes Alfred
    Gschwend, Juergen E.
    Milowsky, Matthew I.
    Schenker, Michael
    Valderrama, Begona P.
    Tomita, Yoshihiko
    Bamias, Aristotelis
    Lebret, Thierry
    Shariat, Shahrokh F.
    Park, Se Hoon
    Agerbaek, Mads
    Jha, Gautam
    Stenner, Frank
    Ye, Dingwei
    Giudici, Fabio
    Dutta, Santanu
    Askelson, Margarita
    Nasroulah, Federico
    Zhang, Joshua
    Brophy, Lynne
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (01)
  • [23] Adjuvant immunotherapy in patients with high-risk muscle-invasive urothelial carcinoma and the potential impact of informative censoring
    Martini, A.
    Raggi, D.
    Joshi, H.
    Fallara, G.
    Nocera, L.
    Belladelli, F.
    Montorsi, F.
    Necchi, A.
    Galsky, M. D.
    EUROPEAN UROLOGY, 2022, 81 : S1331 - S1332
  • [24] Comparison of costs incurred by patients treated with adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma.
    Yin, Xin
    Mitra, Shreya
    Patel, Miraj Y.
    Ranjan, Sandip
    Bhandari, Hitesh
    Potluri, Ravi
    Rosenblatt, Lisa
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [25] A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)
    Monteiro, Fernando Sabino M.
    Soares, Andrey
    Souza, Vinicius Carrera
    Sperandio, Rubens Copia
    Grande, Enrique
    Santoni, Matteo
    Fay, Andre Poisl
    Sasse, Andre Deeke
    CLINICAL GENITOURINARY CANCER, 2022, 20 (05) : 391 - 398
  • [26] Clinical outcomes in post-operative ctDNA-positive muscle-invasive urothelial carcinoma (MIUC) patients after atezolizumab adjuvant therapy
    Powles, T. B.
    Assaf, Z. J.
    Davarpanah, N.
    Hussain, M.
    Oudard, S.
    Gschwend, J. E.
    Albers, P.
    Castellano, D.
    Nishiyama, H.
    Daneshmand, S.
    Grivas, P.
    Sharma, S.
    Sethi, H.
    Aleshin, A.
    Zhang, J.
    Degaonkar, V.
    Bais, C.
    Carter, C. A.
    Bellmunt, J.
    Mariathasan, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S1417 - S1417
  • [27] COST-EFFECTIVENESS OF NIVOLUMAB AS AN ADJUVANT TREATMENT OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA AT HIGH RISK OF RECURRENCE IN SWITZERLAND
    Oniangue-Ndza, C.
    Kamgar, F.
    Schneider, R. P.
    Teitsson, S.
    Knight, C.
    VALUE IN HEALTH, 2022, 25 (12) : S146 - S146
  • [28] Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical local surgery: A prospective, phase II study
    Cao, M.
    Xiao, D.
    Xue, W.
    ANNALS OF ONCOLOGY, 2024, 35
  • [29] HOSPITAL COSTS OF MUSCLE-INVASIVE UROTHELIAL CARCINOMA (MIUC) PATIENTS UNDERGOING RADICAL SURGERY: A FRENCH REAL-WORLD RETROSPECTIVE STUDY BASED ON THE NATIONAL HOSPITALIZATION DATABASE (PMSI)
    Negrier, S.
    Brouquet, A.
    Colrat, F.
    Diez-Andreu, P.
    Chartier, M.
    Prudent, A.
    Gaudin, A. F.
    Benard, S.
    Branchoux, S.
    Roupret, M.
    Bellera, C.
    VALUE IN HEALTH, 2022, 25 (12) : S86 - S86
  • [30] Pathologic response rates between gemcitabine-cisplatin (GC) and methotrexate, vinblastine, doxorubicin hydrochloride, and cisplatin (MVAC) neoadjuvant chemotherapy in muscle-invasive urothelial cell carcinoma of the bladder
    Wright, Jonathan Lawrence
    Lee, Franklin
    Harris, William Proctor
    Cheng, Heather H.
    Zhao, Song
    Champion, Thomas
    Gore, John L.
    Dean, James
    Porter, Michael P.
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345